TRIB
Trinity Biotech PLCNASDAQ
1d
5d
1m
6m
1y
5y
10y
Advanced Chart
  • Tue, Oct. 25, 9:02 AM
    • Trinity Biotech (TRIB) Q3 results: Revenues: $26.1M (+1.2%); Operating Income: $2.7M (-10.0%); Net Loss: ($0.5M) (-104.1%); Loss Per Share: ($0.02) (-103.8%); Non-GAAP EPS: $0.07 (-12.5%); Quick Assets: $84.8M (-0.1%); CF Ops: $5.6M (+51.4%).
    • No guidance given.
    | Tue, Oct. 25, 9:02 AM
  • Tue, Oct. 25, 8:26 AM
    • Trinity Biotech (NASDAQ:TRIB): Q3 EPS of $0.07 in-line.
    • Revenue of $26.1M (+1.3% Y/Y) misses by $0.37M.
    • Press Release
    | Tue, Oct. 25, 8:26 AM
  • Fri, Oct. 7, 11:57 AM
    • Ionis Pharmaceuticals (NASDAQ:IONS) upgraded to Outperform from Market Perform by BMO Capital. Price target raised to $48 (42% upside) from $42.
    • Catalyst Pharmaceuticals (NASDAQ:CPRX) upgraded to Overweight from Neutral by Piper Jaffray. Price target raised to $4 (199% upside) from $1.
    • AmerisourceBergen (NYSE:ABC) upgraded to Market Outperform from Market Perform by Avondale Partners.
    • Alnylam Pharmaceuticals (NASDAQ:ALNY) downgraded to Market Perform from Outperform by Leerink Swann. Price target lowered to $40 (14% upside) from $107. Downgraded to Equal Weight from Overweight by Barclays. Price target lowered to $50 (42% upside) from $85. Downgraded to Neutral from Overweight by JPMorgan. Downgraded to Equal Weight from Overweight by Morgan Stanley. Price target lowered to $36 (3% upside) from $38.
    • Merrimack Pharmaceuticals (NASDAQ:MACK) downgraded to Neutral from Overweight with a $5.75 (2% upside) price target by JPMorgan.
    • Iradimed (NASDAQ:IRMD) downgraded to Neutral from Buy by Roth Capital. Price target lowered to $11.50 (11% upside) from $28.
    • Trinity Biotech (NASDAQ:TRIB) downgraded to Equal Weight from Overweight by Stephens & Co.
    • Depomed (NASDAQ:DEPO) downgraded to Neutral from Buy by Mizuho Securities.
    • Align Technology (NASDAQ:ALGN) downgraded to Neutral from Overweight with a $96 (8% upside) price target by Baird.
    | Fri, Oct. 7, 11:57 AM | 16 Comments
  • Tue, Oct. 4, 12:50 PM
    | Tue, Oct. 4, 12:50 PM
  • Tue, Oct. 4, 11:01 AM
    | Tue, Oct. 4, 11:01 AM
  • Tue, Oct. 4, 9:46 AM
    • Thinly traded micro cap Trinity Biotech (NASDAQ:TRIB) plummets 50% in early trading in response to its announcement that it has withdrawn its 510(k) marketing application from the FDA for its Meritas Point-of-Care Analyzer and the Meritas Troponin-I Test. The company took action following a meeting with the agency during which the reviewers expressed concerns about the filing and suggested the application be withdrawn.
    • The problems relate to the device's operating temperature range and the disparity between the clinical performance data of the Troponin-I test and the most recently cleared laboratory Troponin device. In order to be granted marketing clearance under the 510(k) pathway, Trinity must demonstrate that its Troponin-I test is equivalent to the most recently cleared product.
    • The company stands behind the performance of Troponin-I but admits that there is no certainty that equivalent performance can be achieved. It says that it will initiate an internal review to clarify the best path forward with the platform, a process that may take as long as 12 months to complete.
    • In meantime, Trinity will transfer the technology from its Sweden-based facility to Ireland which will result in the elimination of 40 jobs. It will also record a non-cash charge of over $50M this quarter to account for the costs of the move.
    • Management will host a conference call this morning at 11:00 am ET to discuss the situation.
    | Tue, Oct. 4, 9:46 AM | 1 Comment
  • Tue, Oct. 4, 9:24 AM
    | Tue, Oct. 4, 9:24 AM
  • Thu, Jul. 21, 8:43 AM
    • Trinity Biotech (TRIB) Q2 results: Revenues: $26.3M (+8.2%); Operating Income: $2.4M (-20.0%); Net Income: $2.1M (-22.2%); EPS: $0.09 (-10.0%); Quick Assets: $84.9M (-12.3%).
    • No guidance given.
    | Thu, Jul. 21, 8:43 AM
  • Thu, Jul. 21, 8:25 AM
    • Trinity Biotech (NASDAQ:TRIB): Q2 EPS of $0.09 beats by $0.03.
    • Revenue of $26.29M (+8.4% Y/Y) beats by $1.49M.
    • Press Release
    | Thu, Jul. 21, 8:25 AM
  • Tue, Apr. 19, 9:01 AM
    • Trinity Biotech (TRIB) Q1 results: Revenues: $23.5M (-6.7%); R&D Expense: $1.1M (+10.0%); SG&A: $7M (+11.1%); Operating Income: $1.8M (-58.1%); Net Loss: ($1.3M) (-132.5%); Loss Per Share: ($0.06) (-135.3%); Non-GAAP EPS: $0.06 (-64.7%); Quick Assets: $96.8M (-5.1%).
    • No guidance given.
    | Tue, Apr. 19, 9:01 AM
  • Tue, Apr. 19, 8:34 AM
    • Trinity Biotech (NASDAQ:TRIB): Q1 EPS of $0.06 misses by $0.02.
    • Revenue of $23.5M (-6.9% Y/Y) misses by $0.72M.
    | Tue, Apr. 19, 8:34 AM
  • Thu, Mar. 3, 8:58 AM
    • Trinity Biotech (NASDAQ:TRIB): Q4 EPS of $0.08 misses by $0.01.
    • Revenue of $24.9M (-6.7% Y/Y) misses by $0.91M.
    • The company suspends its annual dividend payment to deploy capital for share buyback.
    | Thu, Mar. 3, 8:58 AM
  • Oct. 22, 2015, 12:47 PM
    | Oct. 22, 2015, 12:47 PM | 1 Comment
  • Oct. 22, 2015, 10:49 AM
    • Trinity Biotech (TRIB +16.7%) Q3 results: Revenues: $25.8M (-5.1%); COGS: $13.8M (-2.8%); R&D Expense: $1.3M (+18.2%); SG&A: $7.5M (+7.1%); Operating Income: $3M (-34.8%); Net Income: $12.3M (+179.5%); Earnings/ADR: $0.097 (-47.3%); Quick Assets: $104.3M (+999%).
    • No guidance given.
    | Oct. 22, 2015, 10:49 AM
  • Oct. 22, 2015, 8:44 AM
    • Trinity Biotech (NASDAQ:TRIB): Q3 EPS of $0.08 misses by $0.01.
    • Revenue of $25.8M (-5.1% Y/Y) beats by $0.38M.
    | Oct. 22, 2015, 8:44 AM | 2 Comments
  • Jul. 28, 2015, 9:45 AM
    • Trinity Biotech (TRIB -3.7%) Q2 results: Revenues: $24.3M (-6.5%); COGS: $12.9M (-4.4%); R&D Expense: $1.3M (+8.3%); SG&A: $6.7M (+4.7%); Operating Income: $3M (-34.8%); Net Income: $2.7M (-37.2%); Earrnings / ADR: $0.10 (-44.4%); Quick Assets: $110.3M (+999%).
    • No guidance given.
    | Jul. 28, 2015, 9:45 AM